Article Navigation
Article Contents
-
Funding
-
Notes
-
Data Availability
-
References
- < Previous
- Next >
Journal Article
, Adana A M Llanos, PhD, MPH Department of Epidemiology, Mailman School of Public Health, Columbia University Irving Medical Center , New York, NY, USA Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center , New York, NY, USA Correspondence to: Adana A. M. Llanos, PhD, MPH, Department of Epidemiology, Columbia University Mailman School of Public Health, 722 W. 168th St, New York, NY 10032, USA (e-mail: al4248@cumc.columbia.edu). Search for other works by this author on: Oxford Academic Jasmine A McDonald, PhD Department of Epidemiology, Mailman School of Public Health, Columbia University Irving Medical Center , New York, NY, USA Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center , New York, NY, USA Search for other works by this author on: Oxford Academic Dede K Teteh, DrPH Department of Health Sciences, Crean College of Health and Behavioral Sciences, Chapman University , Orange, CA, USA Search for other works by this author on: Oxford Academic Traci N Bethea, PhD, MPA Office of Minority Health and Health Disparities Research, Georgetown Lombardi Comprehensive Cancer Center , Washington, DC, USA Search for other works by this author on: Oxford Academic
JNCI: Journal of the National Cancer Institute, Volume 114, Issue 12, December 2022, Pages 1567–1569, https://doi.org/10.1093/jnci/djac169
Published:
17 October 2022
Article history
Received:
03 August 2022
Accepted:
23 August 2022
Corrected and typeset:
17 October 2022
Published:
17 October 2022
- Split View
- Views
- Article contents
- Figures & tables
- Video
- Audio
- Supplementary Data
-
Cite
Cite
Adana A M Llanos, Jasmine A McDonald, Dede K Teteh, Traci N Bethea, Chemical Relaxers and Hair-Straightening Products: Potential Targets for Hormone-Related Cancer Prevention and Control, JNCI: Journal of the National Cancer Institute, Volume 114, Issue 12, December 2022, Pages 1567–1569, https://doi.org/10.1093/jnci/djac169
Close
Search
Close
Search
Advanced Search
Search Menu
Emerging data show that use of permanent hair dyes, chemical relaxers, and straightening products might contribute to increased risk of hormone-related cancers (1-5) and potentially breast tumors with features indicative of more aggressive phenotypes (6). Given the wide use of these products globally, they are an important source of exposure to potentially harmful chemicals, including endocrine-disrupting chemicals—to which we are ubiquitously exposed (7)—and mutagenic and/or genotoxic compounds. The unequal burden of exposure across populations plausibly contributes to cancer inequities as the groups with the greatest exposure also experience poorer cancer outcomes (8). For example, Black women use more hair and menstrual and/or intimate products, and Latina and Hispanic women use more makeup and cosmetics compared with other race and ethnicity groups (9,10), thereby increasing their exposures to hormonally active chemicals. Likewise, Black women are disproportionately diagnosed with aggressive breast tumors (eg, triple-negative, inflammatory), aggressive ovarian tumors (eg, high-grade serous carcinoma), and aggressive types of uterine and endometrial cancers (eg, nonendometrioid carcinoma) and have lower 5-year survival rates and higher mortality rates for these cancers relative to White women (11).
Few studies have examined associations of chemical relaxer and hair-straightening product use with cancer risk, with most studies focusing on the association with breast cancer. An early analysis from the Black Women’s Health Study indicated no association between use of relaxers and breast cancer incidence (12); however, recent data suggest that heavy use relative to nonuse or light use may increase risk (13). Similarly, findings from the Women’s Circle of Health Study indicated no association for ever vs never use of relaxers and breast cancer overall or for Black women; however, increased risk was observed among White women who reported regular use (1). A subsequent analysis from the Women’s Circle of Health Study suggested that use of relaxers for more than 10 years, use before age 12 years, and history of having relaxers applied in both professional settings (ie, salon application) and nonprofessional settings (ie, do-it-yourself, at-home application) were associated with increased risk of higher-grade and larger-sized breast tumors (6). Findings from the Ghana Breast Health Study support the association between relaxer use and increased risk of breast cancer, with greater risk among former than current users (2). Analyses from the Sister Study suggest that use of relaxers is associated with increased risk of breast cancer (3,4) and ovarian cancer (5).
In this issue of the Journal, Chang and colleagues (14) examined associations of recent personal use of 5 types of hair dye products (permanent, semipermanent, and temporary dyes and bleach and highlights) and 2 types of products used to alter the hair’s natural texture (chemical relaxers and straighteners or pressing products and permanent texturizers and body wave products) with risk of endometrial cancer, uterine sarcoma, or other types of uterine cancer in the Sister Study. In this prospective cohort of mostly White women without breast cancer who had at least 1 sister diagnosed with the disease (14), participants completed a questionnaire at baseline that included an assessment of hair product use and frequency of use within the prior 12 months. After an average follow-up of 10.9 years, 378 incident cases of uterine cancer were identified. These included 262 clinically confirmed cases of which 242 (94.7%) were classified as endometrial cancer (based on International Classification of Disease–10 codes) and further defined by histology as either type I (more hormone sensitive, better prognosis) or type II (more aggressive, poorer prognosis) endometrial cancer. Using multivariable-adjusted Cox proportional hazards models with age as the timescale, the investigators observed an 80% higher risk of uterine cancer among users of hair-straightening products, with the risk more than double among frequent users (those reporting use more than 4 times in the prior year) (14). These findings were consistent for type I endometrial cancers; however, associations for type II cases were unreliable because of small sample sizes.
Although the authors acknowledge that adverse effects associated with the use of chemical relaxers is likely more appreciable in Black women because of a higher prevalence of use, initiation at younger ages, and more toxic formulations, the current analysis included an insufficient sample of Black participants—29 (7.7%) of incident uterine cancers and 2523 (7.4%) of eligible cohort members—to determine associations in this group. Nonetheless, this study’s findings represent the first epidemiologic evidence of an association between use of these products and increased risk of uterine cancer (14). The investigators confirmed the robustness of their findings through a series of sensitivity analyses, including restricting the analysis to cases among postmenopausal women, cases that were clinically confirmed uterine cancer, and cases classified as endometrial cancer. Interestingly, although the risk of uterine cancer associated with ever and frequent use of chemical relaxers did not differ by race or ethnicity or by body mass index (BMI), risk estimates differed by physical activity status. The estimates associated with both ever use and more frequent use were higher among participants in the lower tertile of physical activity (less than 32.7 metabolic equivalent hours per week) compared with those reporting activity above that level (14). Further investigation to determine the underlying mechanisms are warranted, especially given the lack of heterogeneity by BMI. Another point to consider, which was not explored in the current analysis, is whether heterogeneity exists by measures of central adiposity (eg, waist circumference, hip circumference, waist-to-hip ratio), which may have an impact on uterine cancer risk beyond overall body fatness estimated using BMI (15).
The preponderance of evidence supporting a positive association of personal care product (PCP) use, especially relaxers (and hair dyes), with breast cancer specifically (16) and hormonally driven cancers generally, suggests that it is time to intervene—despite limitations in cancer epidemiology research (eg, small sample sizes, racial and ethnic heterogeneity, long latency period). The National Cancer Institute has invested in the rigorous review of existing evidence-based cancer control programs to reduce cancer burden and has an online repository of these programs. However, no evidence-based cancer control programs explicitly targeting toxic chemical environmental exposures are listed. As such, the time to build up this evidence base is now. One example of such a program, the Hermosa Study (17), showed that reduced personal exposure to phthalates, parabens, and triclosan chemicals among adolescents is possible through behavioral changes in PCP use. For chemical hair straighteners specifically, mounting evidence supports the prevalence of toxins, carcinogenic effects, chronic and early life exposure, and inequity in exposure, warranting the prioritization of interventions as a means for cancer prevention and control. However, our history (ie, the Food, Drug, and Cosmetic Act, which has done little to enforce regulations on cosmetics, including PCPs since its enactment in 1938) and the present day (ie, Supreme Court decision in West Virginia v Environmental Protection Agency, which ruled to restrict the Environmental Protection Agency’s ability to regulate greenhouse gasses, setting a precedent for other governmental agencies that are mandated to protect our nation’s health) make it clear we have a long way to go in terms of policy interventions to reduce harmful environmental exposures in our communities. Nonetheless, an emergence of funding opportunities focused on reducing environmental impacts (eg, https://www.epa.gov/research-grants/safer-chemicals-research-grants; https://grants.nih.gov/grants/guide/notice-files/NOT-HL-20-788.html, including opportunities specifically targeting endocrine-disrupting chemicals, eg, https://www.challenge.gov/ US Department of Health and Human Services Endocrine-Disrupting Chemicals Innovator Award Competition), new federal policy initiatives (eg, Safer Beauty Bill package, https://www.bcpp.org/resource/safer-beauty-bill-package-press-briefing/), and grassroots advocacy (eg, https://www.thecrownact.com/; https://www.safecosmetics.org/) to reduce exposures from toxic chemicals in PCPs is a step in the right direction (18).
In the United States, Black women experience greater uterine cancer mortality than Asian, Hispanic, or White women, irrespective of histologic subtype or stage at diagnosis (19,20), and statistically significant annual increases have been observed among Black and Hispanic women (20). There is a pressing need to identify and mitigate deleterious risk factors for uterine cancer thereby reducing morbidity and mortality for thousands of women. We applaud Chang and colleagues (14) for adding to the growing body of evidence that PCPs, specifically hair-straightening products, are associated with hormone-related cancers in women. As PCP use may be associated with drivers of uterine cancer risk (21) that differ by race (ie, early age at menarche, increased body fatness, history of uterine fibroids), this literature points toward an opportunity to develop interventions to reduce women’s cancer risk. Interventions focused on PCP use are likely needed across multiple levels to address racialized standards of beauty; a persistent lack of transparency about chemical constituents and formulations in PCPs; culturally acceptable, less toxic alternatives that meet users’ cosmetic needs; and other targets (22). We acknowledge that more research is needed, even as the epidemiologic evidence base has been limited by pervasive challenges. However, we invoke the precautionary principle to call for action even as uncertainties remain (23,24). Many women who use chemical relaxers and hair straighteners begin doing so during adolescence and young adulthood, and use of these products is not limited to the United States. This reality, coupled with global increases in uterine cancer incidence (25), suggests that policy change and evidence-based interventions to reduce exposure to potentially hazardous hair products and other PCPs could be impactful for cancer prevention and control and provide a multitude of benefits for population health.
Funding
No funding was provided in support of the preparation of this editorial.
Notes
Role of the funder: Not applicable.
Disclosures: AAML and DKT serve as Advisory Board members of the Non-Toxic Black Beauty Project with the Campaign for Safe Cosmetics of Breast Cancer Prevention Partners (BCPP). JAM serves on the Board of Directors of BCPP. TNB has no disclosures.
Author contributions: Writing—original draft: AAML, JAM, DKT, and TNB. Writing—review & editing: AAML, JAM, DKT, and TNB.
Data Availability
No data were generated in the preparation of this editorial.
References
1
Llanos AAM Rabkin A Bandera EV
Hair product use and breast cancer risk among African American and White women
.
Carcinogenesis
.
2017
;
38
(
9
):
883
-
892
.
2
Brinton LA Figueroa JD Ansong D
Skin lighteners and hair relaxers as risk factors for breast cancer: results from the Ghana breast health study
.
Carcinogenesis
.
2018
;
39
(
4
):
571
-
579
.
3
Eberle CE Sandler DP Taylor KW White AJ.
Hair dye and chemical straightener use and breast cancer risk in a large US population of Black and White women
.
Int J Cancer
.
2020
;
147
(
2
):
383
-
391
.
4
White AJ Gregoire AM Taylor KW
Adolescent use of hair dyes, straighteners and perms in relation to breast cancer risk
.
Intl J Cancer
.
2021
;
148
(
9
):
2255
-
2263
.
5
White AJ Sandler DP Gaston SA Jackson CL O’Brien KM.
Use of hair products in relation to ovarian cancer risk
.
Carcinogenesis
.
2021
;
42
(
9
):
1189
-
1195
.
6
Rao R McDonald JA Barrett ES
Associations of hair dye and relaxer use with breast tumor clinicopathologic features: findings from the Women’s Circle of Health Study
.
Environ Res
.
2022
;
203
:
111863
.
7
Endocrine Society
. Patient resources: endocrine-disrupting chemicals (EDCs).
2022
. https://www.endocrine.org/patient-engagement/endocrine-library/edcs. Accessed July 26, 2022.
8
Santaliz Casiano A Lee A Teteh D Madak Erdogan Z Trevino L.
Endocrine-disrupting chemicals and breast cancer: disparities in exposure and importance of research inclusivity
.
Endocrinology
.
2022
;
163
(
5
):
1
-
8
.
9
Dodson RE Cardona B Zota AR Robinson Flint J Navarro S Shamasunder B.
Personal care product use among diverse women in California: taking Stock study
.
J Expo Sci Environ Epidemiol
.
2021
;
31
(
3
):
487
-
502
.
10
Collins HN Johnson PI Calderon NM
Differences in personal care product use by race/ethnicity among women in California: implications for chemical exposures [published online ahead of print December 24, 2021]
.
J Expo Sci Environ Epidemiol
.
2021
. doi:
.
11
American Cancer Society
.
Cancer facts & figures 2022
.
Atlanta, GA
:
American Cancer Society
;
2022
. https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2022.html. Accessed July 20, 2022.
OpenURL Placeholder Text
12
Rosenberg L Boggs DA Adams-Campbell LL Palmer JR.
Hair relaxers not associated with breast cancer risk: evidence from the black women’s health study
.
Cancer Epidemiol Biomarkers Prev
.
2007
;
16
(
5
):
1035
-
1037
.
13
Coogan PF Rosenberg L
Palmer
JR
,Cozier
YC
,Lenzy
YM
,Bertrand
KA.
Hair product use and breast cancer incidence in the Black Women’s Health Study
.
Carcinogenesis
.
2021
;
42
(
7
):
924
-
930
.
14
Chang C-J O’Brien KM Keil AP
Use of straighteners and other hair products and incident uterine cancer
.
J Natl Cancer Inst
.
2022
;
114
(12):1636-1645.
OpenURL Placeholder Text
15
Omiyale W Allen NE Sweetland S.
Body size, body composition and endometrial cancer risk among postmenopausal women in UK Biobank
.
Int J Cancer
.
2020
;
147
(
9
):
2405
-
2415
.
16
Xu S Wang H Liu Y
Hair chemicals may increase breast cancer risk: a meta-analysis of 210319 subjects from 14 studies
.
PLoS One
.
2021
;
16
(
2
):
e0243792
.
17
Harley KG Kogut K Madrigal DS
Reducing phthalate, paraben, and phenol exposure from personal care products in adolescent girls: findings from the HERMOSA intervention study
.
Environ Health Perspect
.
2016
;
124
(
10
):
1600
-
1607
.
18
McDonald JA Llanos AAM Morton T Zota AR.
The environmental injustice of beauty products: toward clean and equitable beauty
.
Am J Public Health
.
2022
;
112
(
1
):
50
-
53
.
19
Pinheiro PS Medina HN Koru-Sengul T
Endometrial cancer type 2 incidence and survival disparities within subsets of the US Black population
.
Front Oncol
.
2021
;
11
:
699577
.
20
Clarke MA Devesa SS Hammer A Wentzensen N.
Racial and ethnic differences in hysterectomy-corrected uterine corpus cancer mortality by stage and histologic subtype
.
JAMA Oncol
.
2022
;
8
(
6
):
895
-
903
.
21
Yasin HK Taylor AH Ayakannu T.
A narrative review of the role of diet and lifestyle factors in the development and prevention of endometrial cancer
.
Cancers (Basel)
.
2021
;
13
(
9
):
2149
.
22
Ohayon JL Nost E Silk K Rakoff M Brody JG.
Barriers and opportunities for breast cancer organizations to focus on environmental health and disease prevention: a mixed-methods approach using website analyses, interviews, and focus groups
.
Environ Health
.
2020
;
19
(
1
):
15
.
23
Cohen L Jefferies A.
Environmental exposures and cancer: using the precautionary principle
.
Ecancermedicalscience
.
2019
;
13
:
ed91
.
24
Brody JG Tickner J Rudel RA.
Community-initiated breast cancer and environment studies and the precautionary principle
.
Environ Health Perspect
.
2005
;
113
(
8
):
920
-
925
.
25
Li S Chen H Zhang T
Spatiotemporal trends in burden of uterine cancer and its attribution to body mass index in 204 countries and territories from 1990 to 2019
.
Cancer Med
.
2022
;
11
(
12
):
2467
-
2481
.
© The Author(s) 2022. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com
This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/pages/standard-publication-reuse-rights)
Issue Section:
Editorial
Download all slides
Advertisement
Citations
Views
10,230
Altmetric
More metrics information
Metrics
Total Views 10,230
8,981 Pageviews
1,249 PDF Downloads
Since 10/1/2022
Month: | Total Views: |
---|---|
October 2022 | 4,007 |
November 2022 | 747 |
December 2022 | 524 |
January 2023 | 364 |
February 2023 | 331 |
March 2023 | 285 |
April 2023 | 198 |
May 2023 | 170 |
June 2023 | 123 |
July 2023 | 154 |
August 2023 | 324 |
September 2023 | 122 |
October 2023 | 291 |
November 2023 | 206 |
December 2023 | 140 |
January 2024 | 158 |
February 2024 | 142 |
March 2024 | 170 |
April 2024 | 228 |
May 2024 | 196 |
June 2024 | 249 |
July 2024 | 236 |
August 2024 | 149 |
September 2024 | 221 |
October 2024 | 242 |
November 2024 | 253 |
Altmetrics
Email alerts
Article activity alert
Advance article alerts
New issue alert
Receive exclusive offers and updates from Oxford Academic
Citing articles via
Google Scholar
-
Latest
-
Most Read
-
Most Cited
More from Oxford Academic
Medicine and Health
Books
Journals
Baltimore, Maryland
Houston, Texas
Baltimore, Maryland
Ann Arbor, Michigan
Advertisement